MAPT and early-onset autosomal dominant Alzheimer disease: Following the guidelines for AI-powered nuclear medicine (11), we validate the pipeline using a multisite external dataset from the Alzheimer Disease Neuroimaging Initiative and demonstrate that the proposed pipeline supports more streamlined clinical workflows by providing accurate tau PET quantification without MR and producing uptake estimates that are relevant to cognitive decline.